TY - CHAP M1 - Book, Section TI - Antiviral Agents (Nonretroviral) A1 - Acosta, Edward P. A2 - Brunton, Laurence L. A2 - Hilal-Dandan, Randa A2 - Knollmann, Björn C. PY - 2017 T2 - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e AB - Most antivirals currently available in the U.S. have been developed and approved in the last 25 years. This flurry of activity was driven by successes in rational drug design and approval that began with the antiherpesvirus nucleoside analogue acyclovir (Elion, 1986), whose discovery and development resulted in the awarding of a Nobel Prize to Gertrude Elion and George Hitchings in 1988. Because viruses are obligatory intracellular microorganisms and rely on host biosynthetic machinery to reproduce, there were doubts about the possibility of developing antiviral drugs with selective toxicity, but those doubts have long been erased. Viruses are now obvious targets for effective antimicrobial chemotherapy, and it is certain that the number of available agents in this category will continue to increase. Indeed, the recent development of agents that target the viral protein NS5A has revolutionized treatment of infections of HVB and HVC, and these agents are now allotted a chapter of their own, Chapter 63. Chapter 64 describes chemotherapy for retroviruses. This present chapter covers antiviral agents for nonretroviral infections other than HVB and HVC. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessbiomedicalscience.mhmedical.com/content.aspx?aid=1162545757 ER -